Hepatic Insulin Resistance Is Not Pathway Selective in Humans With Nonalcoholic Fatty Liver Disease
Open accessThe DOI matches its Crossref record; 52 of the 54 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Both glucose and triglyceride production are increased in type 2 diabetes and nonalcoholic fatty liver disease (NAFLD). For decades, the leading hypothesis to explain these paradoxical observations has been selective hepatic insulin resistance wherein insulin drives de novo lipogenesis (DNL) while failing to suppress glucose production. Here, we aimed to test this hypothesis in humans. RESEARCH DESIGN AND METHODS: We recruited obese subjects who met criteria for bariatric surgery with (n = 16) or without (n = 15) NAFLD and assessed 1) insulin-mediated regulation of hepatic and peripheral glucose metabolism using hyperinsulinemic-euglycemic clamps with [6,6-2H2]glucose, 2) fasting and carbohydrate-driven hepatic DNL using deuterated water (2H2O), and 3) hepatocellular insulin signaling in liver biopsy samples collected during bariatric surgery. RESULTS: Compared with subjects without NAFLD, those with NAFLD demonstrated impaired insulin-mediated suppression of glucose production and attenuated—not increased—glucose-stimulated/high-insulin lipogenesis. Fructose-stimulated/low-insulin lipogenesis was intact. Hepatocellular insulin signaling, assessed for the first time in humans, exhibited a proximal block in insulin-resistant subjects: Signaling was attenuated from the level of the insulin receptor through both glucose and lipogenesis pathways. The carbohydrate-regulated lipogenic transcription factor ChREBP was increased in subjects with NAFLD. CONCLUSIONS: Acute increases in lipogenesis in humans with NAFLD are not explained by altered molecular regulation of lipogenesis through a paradoxical increase in lipogenic insulin action; rather, increases in lipogenic substrate availability may be the key.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, Ter Horst et al. [70] demonstrated that glucose-stimulated, insulin-mediated DNL was not elevated in insulin-resistant steatotic livers, calling into question the notion that increased hepatic lipogenesis in human MASLD is primarily driven by pathway-selective insulin action.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [70]
In the citing paper
“In contrast, glucose-stimulated hepatic DNL was significantly higher in control subjects with greater insulin sensitivity.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [70]
In the citing paper
“Moreover, fructose—a substrate that enters hepatocytes independently of insulin—robustly induced gene expression of the active ChREBPβ isoform and stimulated hepatic lipogenesis in obese individuals regardless of MASLD status [70,86].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [70]
In the citing paper
“Thus, in individuals with IR, an increase in hepatic insulin action may not be necessary to explain the upregulated DNL; rather, it is likely driven by an excess supply of lipogenic substrates—including carbohydrates such as fructose as well as amino acids, lactate, and citrate—that fuel hepatic DNL [70,86].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [70]
In the citing paper
“Supporting this perspective, monosaccharides have been shown to activate ChREBP and other key lipogenic transcription factors—including SREBP1c, LXR, and PPARγ—via insulin-independent mechanisms [34,70,83,86,99].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [70]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s002 · Cited by 3,187
Mechanisms of Insulin Action and Insulin Resistance
Petersen, M. C., & Shulman, G. I. (2018) · Physiological Reviews · doi:10.1152/physrev.00063.2017 · Cited by 3,028
Self-citationCalculation of substrate oxidation rates in vivo from gaseous exchange.
Frayn, K. N. (1983) · Journal of Applied Physiology · doi:10.1152/jappl.1983.55.2.628 · Cited by 2,365
Fuller, N. R., Colagiuri, S., Schofield, D., Olson, A. D., Shrestha, R., Holzapfel, C., Wolfenstetter, S. B., Holle, R., Ahern, A. L., Hauner, H., et al. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.139 · Cited by 2,117
INFLUENCES OF GLUCOSE LOADING AND OF INJECTED INSULIN ON HEPATIC GLUCOSE OUTPUT*
Steele, R. (1959) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1959.tb44923.x · Cited by 1,670
The theoretical bases of indirect calorimetry: A review
Ferrannini, E. (1988) · Metabolism · doi:10.1016/0026-0495(88)90110-2 · Cited by 1,580
Szczepaniak, L. S., Nurenberg, P., Leonard, D., Browning, J. D., Reingold, J. S., Grundy, S., Hobbs, H. H., & Dobbins, R. L. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00064.2004 · Cited by 1,562
The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux
Samuel, V. T., & Shulman, G. I. (2016) · Journal of Clinical Investigation · doi:10.1172/jci77812 · Cited by 1,484
Self-citation
Research works printed but not linked: 1
- Jones, 1996, Tracing lipogenesis in humans using deuterated water, Can J Physiol Pharmacol, 74, 755, 10.1139/y96-070 · doi:10.1139/y96-070 · Paper page
Cited by
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
Self-citationWhy does obesity cause diabetes?
Klein, S., Gastaldelli, A., Yki-Järvinen, H., & Scherer, P. E. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2021.12.012 · Cited by 939
A Global View of the Interplay between Non-Alcoholic Fatty Liver Disease and Diabetes
Stefan, N., & Cusi, K. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00003-1 · Cited by 593
Stefan, N., Yki-Järvinen, H., & Neuschwander-Tetri, B. A. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00318-8 · Cited by 392
Role of Insulin Resistance in MAFLD
Sakurai, Y., Kubota, N., Yamauchi, T., & Kadowaki, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084156 · Cited by 448
Molecular aspects of fructose metabolism and metabolic disease
Herman, M. A., & Birnbaum, M. J. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.09.010 · Cited by 290
Bo, T., Gao, L., Yao, Z., Shao, S., Wang, X., Proud, C. G., & Zhao, J. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.04.006 · Cited by 293
The role of hepatokines in NAFLD
Stefan, N., Schick, F., Birkenfeld, A. L., Häring, H.-U., & White, M. F. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.01.006 · Cited by 282
Lipid metabolism in MASLD and MASH: From mechanism to the clinic
Carli, F., Della Pepa, G., Sabatini, S., Vidal Puig, A., & Gastaldelli, A. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101185 · Cited by 147
Important Hormones Regulating Lipid Metabolism
Zhang, D., Wei, Y., Huang, Q., Chen, Y., Zeng, K., Yang, W., Chen, J., & Chen, J. (2022) · Molecules · doi:10.3390/molecules27207052 · Cited by 173
Self-citationHepatic glucose metabolism in the steatotic liver
Scoditti, E., Sabatini, S., Carli, F., & Gastaldelli, A. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00888-8 · Cited by 134
MASH: the nexus of metabolism, inflammation, and fibrosis
Steinberg, G. R., Carpentier, A. C., & Wang, D. (2025) · Journal of Clinical Investigation · doi:10.1172/jci186420 · Cited by 156
Ratziu, V., Scanlan, T. S., & Bruinstroop, E. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.10.018 · Cited by 128
Palma, R., Pronio, A., Romeo, M., Scognamiglio, F., Ventriglia, L., Ormando, V. M., Lamazza, A., Pontone, S., Federico, A., & Dallio, M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11133649 · Cited by 125
Hu, Y., He, W., Huang, Y., Xiang, H., Guo, J., Che, Y., Cheng, X., Hu, F., Hu, M., Ma, T., et al. (2021) · Hepatology · doi:10.1002/hep.32045 · Cited by 128
Luukkonen, P. K., Porthan, K., Ahlholm, N., Rosqvist, F., Dufour, S., Zhang, X.-M., Lehtimäki, T. E., Seppänen, W., Orho-Melander, M., Hodson, L., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.10.008 · Cited by 97
Self-citationInsulin and aging – a disappointing relationship
Kolb, H., Kempf, K., & Martin, S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1261298 · Cited by 101
Truong, X. T., & Lee, D. H. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0644 · Cited by 84
Excessive Gluconeogenesis Causes the Hepatic Insulin Resistance Paradox and Its Sequelae
Onyango, A. N. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e12294 · Cited by 93
Hepatic insulin receptor: new views on the mechanisms of liver disease
Lee, W., Najjar, S. M., Kahn, C. R., & Hinds, T. D. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155607 · Cited by 79
Skeletal muscle and MASLD: Mechanistic and clinical insights
Marjot, T., Armstrong, M. J., & Stine, J. G. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000711 · Cited by 82
Pafili, K., Kahl, S., Mastrototaro, L., Strassburger, K., Pesta, D., Herder, C., Pützer, J., Dewidar, B., Hendlinger, M., Granata, C., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.08.010 · Cited by 67
Dysregulation of hepatic metabolism with obesity: factors influencing glucose and lipid metabolism
Nagarajan, S. R., Cross, E., Sanna, F., & Hodson, L. (2021) · Proceedings of The Nutrition Society · doi:10.1017/s0029665121003761 · Cited by 71
The role of adipose tissue dysfunction in hepatic insulin resistance and T2D
Sancar, G., & Birkenfeld, A. L. (2024) · Journal of Endocrinology · doi:10.1530/joe-24-0115 · Cited by 79
Adaptive and maladaptive roles for ChREBP in the liver and pancreatic islets
Katz, L. S., Baumel-Alterzon, S., Scott, D. K., & Herman, M. A. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100623 · Cited by 62
Hormonal regulation of metabolism—recent lessons learned from insulin and estrogen
Tao, Z., & Cheng, Z. (2023) · Clinical Science · doi:10.1042/cs20210519 · Cited by 72
Mucinski, J. M., Salvador, A. F., Moore, M. P., Fordham, T. M., Anderson, J. M., Shryack, G. E., Cunningham, R. P., Lastra, G., Gaballah, A. H., Diaz‐Arias, A. A., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.06.017 · Cited by 64
Metabolic syndrome and its association with nonalcoholic steatohepatitis
Bril, F., Sanyal, A., & Cusi, K. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.002 · Cited by 52
Dall’Agnese, A., Platt, J. M., Zheng, M., Friesen, M., Dall’Agnese, G., Blaise, A. M., Spinelli, J. B., Henninger, J. E., Tevonian, E. N., Hannett, N. M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35176-7 · Cited by 53
Samy, A. M., Kandeil, M. A., Sabry, D., Abdel-Ghany, A. A., & Mahmoud, M. O. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30387 · Cited by 60
Mertens, J., Block, C. E. M. D., Spinhoven, M. J., Driessen, A. L. C., Francque, S., & Kwanten, W. J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.768576 · Cited by 54
Nonalcoholic fatty liver disease: Current therapies and future perspectives in drug delivery
Domingues, I., Leclercq, I. A., & Beloqui, A. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.09.040 · Cited by 45
Upregulation of WDR6 drives hepatic de novo lipogenesis in insulin resistance in mice
Yao, Z., Gong, Y., Chen, W., Shao, S., Song, Y., Guo, H., Li, Q., Liu, S., Wang, X., Zhang, Z., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00896-7 · Cited by 48
MASH as an emerging cause of hepatocellular carcinoma: current knowledge and future perspectives
Karin, M., & Kim, J. Y. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13685 · Cited by 51
Vazquez-Borrego, M. C., del Río-Moreno, M., & Kineman, R. D. (2021) · Cells · doi:10.3390/cells10102532 · Cited by 44
Liver insulinization as a driver of triglyceride dysmetabolism
Cook, J. R., Hawkins, M. A., & Pajvani, U. B. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00843-6 · Cited by 35
Sabatini, S., Sen, P., Carli, F., Pezzica, S., Rosso, C., Lembo, E., Verrastro, O., Daly, A. K., Govaere, O., Cockell, S., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101820 · Cited by 45
Fu, X., Fletcher, J. A., Deja, S., Inigo-Vollmer, M., Burgess, S. C., & Browning, J. D. (2023) · Journal of Clinical Investigation · doi:10.1172/jci167442 · Cited by 30
The Impact and Burden of Dietary Sugars on the Liver
Huneault, H. E., Tovar, A. R., Sanchez-Torres, C., Welsh, J. A., & Vos, M. B. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000297 · Cited by 31
In vivo 2H/13C flux analysis in metabolism research
Bednarski, T. K., Rahim, M., & Young, J. D. (2021) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2021.04.005 · Cited by 26
Rho-Kinase as a Therapeutic Target for Nonalcoholic Fatty Liver Diseases
Sousa‐Lima, I., Kim, H. J., Jones, J. G., & Kim, Y. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0197 · Cited by 28
Antipsychotic-Induced Alterations in Lipid Turnover
Pereira, S., Au, E., Agarwal, S. M., Wright, D. C., & Hahn, M. (2023) · Endocrinology · doi:10.1210/endocr/bqad025 · Cited by 24
Liu, J., Guan, L., Zhao, M., Li, Q., Song, A., Gao, L., Lin, H., & Zhao, J. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s316864 · Cited by 19
Intact Fasting Insulin Identifies Nonalcoholic Fatty Liver Disease in Patients Without Diabetes
Bril, F., McPhaul, M. J., Kalavalapalli, S., Lomonaco, R., Barb, D., Gray, M. E., Shiffman, D., Rowland, C. M., & Cusi, K. J. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab417 · Cited by 17
Rabbani, N., & Thornalley, P. J. (2025) · Clinical Science · doi:10.1042/cs20257727 · Cited by 17
Silva, M. H. A. D. D., Hewawasam, R. P., Kulatunge, C. R., & Mudiyanselage, A. C. R. (2022) · BMC Pediatrics · doi:10.1186/s12887-022-03575-w · Cited by 14
Reis-Costa, A., Belew, G. D., Viegas, I., Tavares, L. C., Meneses, M. J., Patrício, B. G., Gastaldelli, A., Macedo, M. P., & Jones, J. G. (2024) · Nutrients · doi:10.3390/nu16142186 · Cited by 16
Maffeis, C., Piona, C. A., Morandi, A., Marigliano, M., Morotti, E., Mancioppi, V., Caiazza, E., Zusi, C., Emiliani, F., Mantovani, A., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15961 · Cited by 12
Yildirim, V., ter Horst, K. W., Gilijamse, P. W., van Harskamp, D., Schierbeek, H., Jansen, H., Schimmel, A. W. M., Nieuwdorp, M., Groen, A. K., Serlie, M. J. M., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.166905 · Cited by 10
Self-citationHigh-fat-diet-induced hepatic insulin resistance per se attenuates murine de novo lipogenesis
Goedeke, L., Strober, J. W., Suh, R., Paolella, L. M., Li, X., Rogers, J. C., Petersen, M. C., Nasiri, A. R., Casals, G., Kahn, M., et al. (2024) · iScience · doi:10.1016/j.isci.2024.111175 · Cited by 15
Self-citationKattapuram, N., Zhang, C., Muyyarikkandy, M. S., Surugihalli, C., Muralidaran, V., Gregory, T., & Sunny, N. E. (2021) · Metabolites · doi:10.3390/metabo11050272 · Cited by 11
Cell-specific regulation of insulin action and hepatic fibrosis by CEACAM1
Aldroubi, B., Najjar, J. A., Youssef, T., Rizk, C., Abuamreh, B. A. M., Aramouni, K., Ghadieh, H. E., & Najjar, S. M. (2024) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.48 · Cited by 8
Challenges of Spatially Resolved Metabolism in Cancer Research
Lane, A. N., Higashi, R. M., & Fan, T. W. ‐. (2024) · Metabolites · doi:10.3390/metabo14070383 · Cited by 9
Tsakiridis, E. E., & Steinberg, G. R. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70624 · Cited by 9
Fructose and follistatin potentiate acute MASLD during complete hepatic insulin resistance
Tao, R., Stöhr, O., Tok, O., Andrés-Hernando, A., Qiu, W., He, B., Wang, C., Grøntved, L., Burant, C., Hui, S. T., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-66296-5 · Cited by 7
Petersen, M. C., Smith, G. I., Farabi, S. S., Palacios, H. H., Shankaran, M., Hellerstein, M. K., Patterson, B. W., & Klein, S. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.07.020 · Cited by 6
Laupsa‐Borge, J., Grytten, E., Bohov, P., Bjørndal, B., Strand, E., Skorve, J., Nordrehaug, J. E., Berge, R. K., Rostrup, E., Mellgren, G., et al. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1020678 · Cited by 6
Chai, H., Gao, S., Dai, Y., Dai, J., Zhao, G., & Zhu, J. (2024) · British Journal Of Nutrition · doi:10.1017/s0007114524001442 · Cited by 5
Novel Antidiabetic Strategies and Diabetologists' Views in Nonalcoholic Steatohepatitis
Kahl, S., Pützer, J., & Roden, M. (2022) · Seminars in Liver Disease · doi:10.1055/s-0041-1732354 · Cited by 5
Strober, J. W., Siebel, S., Murray, S. F., Rodríguez, M. G., Gonzalez, C. R.-N., & Vatner, D. F. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100838 · Cited by 4
Self-citationA microphysiological model of human MASLD reveals paradoxical response to resmetirom
Hellen, D. J., Ungerleider, J. L., Tevonian, E. N., Sphabmixay, P., Roy, P., Meimetis, N., Presutti, F., Williams, A. M., Ogi, R., Lewis, C. A., et al. (2026) · Communications Biology · doi:10.1038/s42003-025-09484-9 · Cited by 4
Cai, Y., Nie, T., Luo, X., Wu, Y., & Wu, J. (2026) · Acta Biomaterialia · doi:10.1016/j.actbio.2026.01.043 · Cited by 4
Westcott, F., Nagarajan, S. R., Parry, S. A., Savic, D., Green, C., Marjot, T., Johnson, E. M., Cornfield, T., Mózes, F. E., O’Rourke, P., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae123 · Cited by 6
Choi, Y., Song, J. E., Lim, S.-H., & Song, H. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1663958 · Cited by 3
Molecular mechanisms and pathogenesis of MASH
Gallage, S., Govaere, O., Anstee, Q. M., Shulman, G. I., Tacke, F., & Heikenwälder, M. F. (2026) · Nature · doi:10.1038/s41586-026-10529-0 · Cited by 9
Self-citationKlein, S., & Yoshino, M. (2021) · Science · doi:10.1126/science.abj7375 · Cited by 3
Maffeis, C., Morandi, A., Zusi, C., Olivieri, F., Fornari, E., Cavarzere, P., Piona, C. A., Corradi, M., Emiliani, F., Ros, A. D., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16081 · Cited by 3
Role of ChREBP–PPARα–FGF21 Axis in Metabolic Dysfunction of MASLD
Girón, K. M. P., Nazará, Z., Maldonado‐González, M., Martínez‐López, E., Sánchez-Muñoz, M. P., Bautista-López, C. A., Aldana-Aguiñaga, M. S., Domínguez-Rosales, J. A., Vargas‐Guerrero, B., & Ruiz‐Madrigal, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311425 · Cited by 3
Substrate supply, compartmentation, and utilization in hepatic de novo lipogenesis
Pape, D. J., & Taylor, E. B. (2026) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2026.01.001 · Cited by 2
Reducing complications of metabolic dysfunction–associated steatotic liver disease
Wada, N., Iwaki, M., Kobayashi, T., Nakajima, A., & Yoneda, M. (2025) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2025.2502549 · Cited by 1
Xu, H., Ma, X., Chen, F., & Zhou, B. (2026) · Cardiovascular Therapeutics · doi:10.1155/cdr/3055531 · Cited by 1
Mekki, Y. M., Park, J., Alzaareer, Z., Hussain, Z., Gulzar, A., Elzouki, A. Y. A., Güemes, A., & Zughaier, S. M. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-01876-w · Cited by 1
Type 2 Diabetes Mellitus: Molecular Pathogenesis and Therapeutic Interventions
Fei, S., Xiong, X., Zhang, L., Zhang, J., Chan, L. W. C., Jiang, H., Xiong, Q., Changtao, H., Chen, J., & Yang, S. (2026) · MedComm · doi:10.1002/mco2.70895 · Cited by 1
Gastaldelli, A., Choi, E., Conde‐Knape, K., Göransson, O., Krook, A., Lehtonen, S. H., Roden, M., Schrauwen, P., Sparks, L. M., & Heni, M. (2026) · Diabetologia · doi:10.1007/s00125-026-06853-9 · Cited by 3
Physiopathologie de la stéatose hépatique non-alcoolique (NAFLD)
Parlati, L., Régnier, M., Postic, C., & Guillou, H. (2023) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2023.03.005 · Cited by 3
NAFLD: Hepatische Insulinresistenz ist beim Menschen nicht signalwegselektiv
Brudermanns, B. (2021) · Diabetologie und Stoffwechsel · doi:10.1055/a-1317-5090
Exercise An Important Component in The Treatment and Prevention of Obesity
PF, P. F. W. (2022) · American Journal of Biomedical Science & Research · doi:10.34297/ajbsr.2022.16.002274
Mucinski, J. M. (2022) · MOspace Institutional Repository (University of Missouri) · doi:10.32469/10355/93980
Combatting the Fructose Epidemic: Fruitful or Fruitless?
Buziau, A. M. (2023) · Research Publications (Maastricht University) · doi:10.26481/dis.20231113ab
Proteomic Signature of Liver Injury Across the Spectrum of Insulin Resistance
Prieur, X., & Langin, D. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf627
Altered Molecular Regulation of TUG Is a Central Feature of Insulin-Resistant Human Adipose Tissue
Strober, J. W., ter Horst, K. W., Sung, D., Jongejan, A., Slusher, A. L., Gassaway, B. M., Tarabra, E., Paulo, J. A., Shuken, S. R., Gygi, S. P., et al. (2025) · Diabetes · doi:10.2337/db25-0488
Self-citationRôle de l'isoforme A du récepteur de l'insuline dans l'homéostasie et la carcinogenèse hépatiques
Léandre, F. (2024) · theses.fr (ABES) · doi:10.70675/df1bc445z5d98z462dzbc59za0d4015bcf04
Inter-organ communication in physiology and pathophysiology : a role for the ChREBP-FGF21 axis?
Carbinatti, T. (2024) · theses.fr (ABES) · doi:10.70675/5d147ab4zad37z4f6bzac51z32a08efeaa51
Insulin Clearance Along the Liver–Kidney Axis: Implications for Insulin Action
Perdomo, G., Cózar‐Castellano, I., & Najjar, S. M. (2026) · Metabolites · doi:10.3390/metabo16070439
Glycerol 3-phosphate activates lipid metabolism through GATOR2-dependent regulation of mTORC1
Kwon, H., Yamada, S., Meng, L., Kwon, M., Xu, H., Chi, J., Radovick, S., Gu, H., He, L., & Wondisford, F. E. (2026) · Science Signaling · doi:10.1126/scisignal.aeb7989
Insulin Action in Liver, Skeletal, Muscle, and Adipose Tissue: A Focus on Humans
Trinks, N., Schön, M., Gancheva, S., & Roden, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-11985-9.00009-3
Kotlyarov, S. N., Котлярова, А. А., Catanzaro, R., & Marotta, F. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198614
Insulin resistance: A key player in the onset of diverse disease pathologies
Aswal, P., Setya, S., Jangwan, N. S., Farswan, A. S., & Singh, M. F. (2026) · Vietnam Journal of Science and Technology/Science and Technology · doi:10.15625/2525-2518/19547
Metadata
- Authors
- ter Horst, K. W., Vatner, D. F., Zhang, D., Cline, G. W., Ackermans, M. T., Nederveen, A. J., Verheij, J., Demirkiran, A., van Wagensveld, B. A., Dallinga-Thie, G. M., Nieuwdorp, M., Romijn, J. A., Shulman, G. I., & Serlie, M. J.
- Affiliations
- Department of Endocrinology and Metabolism, Amsterdam University Medical Center, Amsterdam, the Netherlands
- Yale University (US)
- Department of Clinical Chemistry, Laboratory of Endocrinology, Amsterdam University Medical Center, Amsterdam, the Netherlands
- Amsterdam UMC Location University of Amsterdam (NL)
- Department of Surgery, Red Cross Hospital, Beverwijk, the Netherlands
- Department of Surgery, OLVG West, Amsterdam, the Netherlands
- Department of Vascular Medicine, Amsterdam University Medical Center, Amsterdam, the Netherlands
- Amsterdam University Medical Centers (NL)
- Corresponding author
- Serlie, Mireille J.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-12-08
- Volume
- 44
- Issue
- 2
- Pages
- 489-498
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC7818337
- OpenAlex
- W3110973280
- Cited by
- 88
- References
- 54
- Citations by year
- 2026: 15 · 2025: 11 · 2024: 20 · 2023: 17 · 2022: 9 · 2021: 16
- FWCI
- 7.52
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (acceptedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion, other-oa)
- Funders
- European Commission (FP7-EU 305707)
- National Institutes of Health (R01-DK-124272, K23-DK-10287)
- ZonMw (VIDI 016.146.327)
- Hartstichting (CVON IN-CONTROL, R01-DK-113984, R01-DK-119968, P30-DK-45735)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
- Keywords
- non-alcoholic fatty liver disease, hepatic insulin resistance, de novo lipogenesis, hepatic glucose production, insulin signaling, insulin receptor, ChREBP, fructose, hyperinsulinemic-euglycemic clamp, bariatric surgery, obesity
- MeSH terms
- Diabetes Mellitus, Type 2, Humans, Insulin, Insulin Resistance, Liver, Lipogenesis, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.